Corcept Therapeutics (CORT) Debt to Equity (2012 - 2017)

Corcept Therapeutics has disclosed Debt to Equity across 6 years of filings, most recently posting $0.07 for Q2 2017.

• Debt to Equity for Q2 2017 came in at $0.07, down 92.05% year-over-year; the trailing twelve-month figure through Jun 2017 was $0.07 (down 92.05% YoY), and the FY2016 annual result was $0.35, down 76.16% from the prior year.
• Debt to Equity came in at $0.07 for Q2 2017 at Corcept Therapeutics, down from $0.2 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $10.15 in Q2 2014 to a low of -$26.31 in Q3 2014.
• The 5-year median for Debt to Equity is $1.0 (2013), against an average of -$0.29.
• Peak annual rise in Debt to Equity reached 1109.01% in 2014, while the deepest fall reached 2437.21% in 2014.
• Corcept Therapeutics' Debt to Equity stood at $1.67 in 2013, then plunged by 699.5% to -$10.0 in 2014, then surged by 114.86% to $1.49 in 2015, then sank by 76.16% to $0.35 in 2016, then plunged by 80.49% to $0.07 in 2017.
• The last three Debt to Equity figures came in at $0.07 (Q2 2017), $0.2 (Q1 2017), and $0.35 (Q4 2016), per Business Quant data.